Are payers treating orphan drugs differently?

Journal of Market Access and Health Policy

Volumn 2, Issue 1, 2014, Pages

  Cohen, Joshua P ^a   Felix, Abigail ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

orphan drugs; pricing; reimbursement

Indexed keywords

EID: 84916915741     PISSN: None     EISSN: 20016689     Source Type: Journal    
DOI: 10.3402/jmahp.v2.23513     Document Type: Article

References (23)

1. Orphan Drug Regulations (57 FR 62076), December 29, 1992 and 21 CFR Part 316 et seq.
2. BlankartCR, StargardtT, SchreyoggJ.Availability of and access to orphan drugs: An international comparison of pharmaceutical treatments for pulmonary arterial hypertension, Fabry disease, hereditary angioedema and chronic myeloid leukemia. Pharmacoeconomics. 2011; 29: 63–82.
3. KaitinKI. U.S. orphan product designations more than doubled from 2000–02 to 2006–08: Tufts Center for the Study of Drug Development Impact Report. 2010; Boston, MA: Tufts Center for the Study of Drug Development.1–5.
4. European Parliament.Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products. Official J Eur Comm. 2000. 22 1. 2000, L 18/1.
5. Seoane-VazquezE, Rodriguez-MonguioR, SzeinbachSL, VisariaJ.Incentives for orphan drug research and development in the United States. Orphanet J Rare Dis. 2008; 3: 33.
6. Rosenberg-YungerZ, DaarA, ThorsteinsdottirH, MartinD.Priority setting for orphan drugs: An international comparison. Health Pol. 2011; 10: 25–34.
7. HydeR, DobrovolnyD.Orphan drug pricing and payer management in the United States: Are we approaching the tipping point?. Am Health Drug Benefits. 2010; 3(1):15–23.
8. LargentE, PearsonS.Which orphans will find a home: The rule of rescue in resource allocation for rare diseases. Hastings Cent Rep. 2012; 42: 27–34.
9. KlepserD, HuetherJ, HandkeL, WilliamsC.Effect on drug utilization and expenditures of a cost-share change from co-payment to co-insurance. J Manag Care Pharm. 2007; 13: 765–77. [PubMed Abstract].
10. CohenJP, MalinsA, ShahpurwalaZ.Compared to US practice, evidence-based reviews in Europe appear to lead to lower prices for some drugs. Health Aff. 2013; 32: 762–70.
11. BennettS. Orphan drug prices under siege in austerity-minded Europe. Bloomberg News. 7 April 2013. Available from: http://www.bloomberg.com/news/2013-04-07/orphan-drug-prices-under-siege-in-austerity-minded-europe.html [cited 1 November 2013].
12. Hughes-WilsonW, PalmaA, SchuurmanA, SimoensS.Paying for the orphan drug system: Break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments?. Orphanet J Rare Dis. 2012; 7: 74.
13. DenisA, SimoensS, FostierC, MergaertL, CleemputI. KCE reports 112C; Policies for orphan diseases and orphan drugs. Belgian Health Care Knowledge Centre. 2009. Available from: http://ec.europa.eu/health/ph_threats/non_com/docs/policies_orphan_en.pdf [cited 1 November 2013].
14. FadenL, HuskampH. FieldM, BoatT. Medicare Part D coverage and reimbursement of orphan drugs. Institute of Medicine Committee on Accelerating Rare Diseases Research and Orphan Product Development. Rare diseases and orphan products: Accelerating research and development. 2010; Washington DC: National Academies Press.309–343.
15. CohenJ, YoungB, RochonS, FadenL.Are Medicare plans complying with CMS regulation?. Expert Rev Pharmacoecon Outcomes Res. 2008; 8(2):133–8.
16. CohenJ, FadenL, PredarisS, YoungB.Patient access to pharmaceuticals: An international comparison. Eur J Health Econ. 2007; 8(3):253–66.
17. HargraveE, HoadleyJ, ThompsonJ. Coverage and pricing of drugs that can be covered under Part B and Part D. 2007; Washington DC: MedPAC.
18. Medicare Plan Finder.Available from: https://www.medicare.gov/find-a-plan/questions/home.aspx?AspxAutoDetectCookieSupport=1 [cited 23 October 2013].
19. Forgotten conditions: Misdiagnosed and unsupported, how patients are being let down. Available from: http://www.2020health.org/2020health/Publication-2012/Wellbeing-and-Public-Health/forgotten-conditions.html [cited 20 September 2013].
20. DupontA, van WilderP.Access to orphan drugs despite poor quality of clinical evidence. Br J Clin Pharmacol. 2011; 71(4):488–96.
21. HerperM. Inside the pricing of a $300,000-a-year drug. Forbes Magazine. 1 January 2013. Available from: http://www.forbes.com/sites/matthewherper/2013/01/03/inside-the-pricing-of-a-300000-a-year-drug/ [cited 1 November 2013].
22. TillesS, BorishL, CohenJ.Management of hereditary angioedema in 2012: Scientific and pharmacoeconomic perspectives. Ann Allergy Asthma Immunol. 2013; 110(2):70–4.
23. ScheyC, MilanovaT, HutchingsA.Estimating the budget impact of orphan medicines in Europe: 2010–2020. Orphanet J Rare Dis. 2011; 6: 62.